Skip to main content
Premium Trial:

Request an Annual Quote

New York State OKs Pathwork Dx's Tissue of Origin Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today announced it has received approval from the New York State Department of Health to offer its Tissue of Origin testing service.

As a result the Redwood, Calif., company will be able to offer the service, which it said is the only FDA-cleared tissue of origin testing service in New York state.

The test helps identify the origin of challenging tumors and increases pathologist and oncologist confidence in the diagnosis of cancer, according to Pathwork. The test uses small amounts of formalin fixed, paraffin-embedded tumor tissue and measures gene expression levels of more than 2,000 genes. It received FDA clearance in June for use with FFPE tissues and is the only FDA-cleared molecular diagnostic test for tissue of origin.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.